產(chǎn)品[
CRL-2238 SNU-423 人肝細(xì)胞癌
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
CRL-2238 SNU-423 人肝細(xì)胞癌
產(chǎn)品型號(hào):
CRL-2238
產(chǎn)品廠商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡(jiǎn)單介紹
CRL-2238 SNU-423 人肝細(xì)胞癌，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和Z優(yōu)培養(yǎng)條件！
CRL-2238 SNU-423 人肝細(xì)胞癌
的詳細(xì)介紹
CRL-2238 SNU-423 人肝細(xì)胞癌
|
|
CRL-2238?
|
|
$417.00
|
|
|
SNU-423
|
|
|
J Park
|
|
Biosafety Level:
|
2 [CELLS CONTAIN HEPATITIS B VIRUS ]
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: liver
Tumor Stage: grade III/IV
Disease: pleomorphic hepatocellular carcinoma
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Blood Type B; Rh +
|
|
|
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 10,13
D16S539: 9
D5S818: 10
D7S820: 12
THO1: 6,9
TPOX: 8
vWA: 15
|
|
|
aneuploid; modal number = 79
|
|
|
40 years
|
|
|
male
|
|
|
Asian
|
|
|
ATCC complete growth medium: RPMI 1640 medium, 90%; heat-inactivated fetal bovine serum, 10%
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:5 is recommended
Medium Renewal: Every 2 to 3 days
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.
Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
72 hrs
|
|
|
22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080
|
|
ATCC® Number: CRL-2238? Price: $417.00
Designations: SNU-423
Depositors: J Park
Biosafety Level: 2 [CELLS CONTAIN HEPATITIS B VIRUS ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: liver
Tumor Stage: grade III/IV
Disease: pleomorphic hepatocellular carcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Antigen Expression: Blood Type B; Rh +
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 10,13
D16S539: 9
D5S818: 10
D7S820: 12
THO1: 6,9
TPOX: 8
vWA: 15
Cytogenetic Analysis: aneuploid; modal number = 79
Age: 40 years
Gender: male
Ethnicity: Asian
Comments: SNU-423 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus doxorubicin.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum.
After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum.
Grossly, the original tumor was single nodular with perinodular extensions.
Histologically, it was trabecular type.
The cultured cells are multinucleated.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
Propagation: ATCC complete growth medium: RPMI 1640 medium, 90%; heat-inactivated fetal bovine serum, 10%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:5 is recommended
Medium Renewal: Every 2 to 3 days
Remove spent medium, add fresh 0.25% trypsin, 0.03% EDTA solution, rinse and remove trypsin.
Add fresh trypsin solution (1 to 2 ml) and let the culture sit at room temperature (or at 37C) until the cells detach.
Preservation: Culture medium, 95%; DMSO, 5%
Doubling Time: 72 hrs
References: 22872: Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080
